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ABSTRACT
Objective: The objective of the study was to assess the adverse drug reactions (ADRs) of antiretroviral therapy along with its causality, severity, and 
preventability.
Method: A prospective as well as a retrospective observational study with a sample size of 260, jointly conducted in the Department of Pharmacology 
and antiretroviral therapy (ART) center of N.S.C.B. Medical College Jabalpur, India, from March 2016 to July 2017. We observed various ADRs to ART 
in human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients and assessed causality, severity, and preventability 
of the reported ADRs as per the standard scales.
Results: A total of 260 patients were enrolled of which 220 (84.6%) patients developed a total of 425 ADRs. Maximum 51.7% of ADRs were caused by 
TLE followed by 37% with ZLN regimen. Most common ADRs were dizziness 18.6%, rashes 14.6%, anemia 10.6%, and vomiting 6.6%. Dizziness and 
rashes are mainly caused by TLE and ZLN regimen, respectively. Management of ADRs with a change in the regimen was applied as an interventional 
tool in 40% of the patients. Causality assessment as per the WHO-UMC scale showed that 55.5% of ADR were probable and 45.5% were possible. 
84.5% of ADR was not preventable, while 15.5% of ADRs were probably preventable. 38% of ADRs were mild, 56% were moderate, and 6% were 
severe in nature.
Conclusion: Antiretrovirals, however, the milestone for the treatment of HIV/AIDS have very high potential for developing ADRs. Hence, active 
pharmacovigilance is needed for not only safety of the patients but also compliance to the treatment which is necessary for optimal therapeutic 
outcomes and to improve quality of life.
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INTRODUCTION
The word “pharmacovigilance (PV)” is derived from pharmakon 
(Greek: Drug) and vigilare (Latin: To keep watch) also known as drug 
safety, refers to the process of continuous monitoring for unwanted 
effects and other safety-related aspects of marketed drugs [1]. PV 
heavily focuses on adverse drug reactions (ADRs), which is defined by 
the WHO as “A response to a drug which is noxious and unintended, 
and which occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modification of physiological 
function” [2]. The thalidomide disaster, detected in 1961, is a milestone 
in origin and further development of PV. The WHO started a program 
for international drug monitoring in 1968. The Uppsala Monitoring 
Centre (UMC) was established in 1978 to support the WHO Programme 
for International Drug Monitoring. At present, 134 countries are 
participating in the PV program which is centrally coordinated by 
the WHO with its collaborating centre in Uppsala, Sweden. The UMC 
(UMC, WHO) maintains the global ADR database which contains more 
than 12 million reports in the software “Vigibase,” a web-based online 
system [3].
Monitoring of ADRs is especially important when treatment is 
being scaled up, such as antiretroviral therapy (ART) for the human 
immunodeficiency virus (HIV)/acquired immunodeficiency syndrome 
(AIDS) patients. Although ART is very effective, these drugs are highly 
toxic and are associated with various ADRs; therefore, many patients 
warrant withdrawal of the drugs or even discontinuation of treatment 
resulting in treatment failure. Hence, PV plays an important role in the 
management of treatment and ensuring safety in HIV patients [4].
AIDS is a global problem. It has now been reported from more than 
190 countries around the world, and a pool of HIV infected persons in 
Africa and Asia is large and expanding. Since the start of the epidemic, 
an estimated 76.1 million people have become infected with HIV, and 
35 million people have died of AIDS-related illnesses. In only 2016, 1 
million people died from AIDS-related illnesses, and 1.8 million people 
became newly infected worldwide. According to the UNAIDS, about 
36.7 million people were living with HIV globally by the end of 2016. 
Among them, 19.5 million people have access to ART [5].
The world has committed to end the AIDS epidemic by 2030. UNAIDS 
recommends a Fast-Track approach to achieve the 90–90–90 treatment 
target by 2020, whereby 90% of people living with HIV should know 
their HIV status, 90% of people who know their HIV-positive status are 
accessing treatment, and 90% of people on treatment have suppressed 
viral loads. Global consensus and leadership have driven greater 
investment of financial and human capital, and mounting clinical 
experience and research, improved treatment regimens and diagnostics 
and reductions in the price of medicines have created gains in efficiency 
and effectiveness [6].
In India, approximately 2.1 million people are living with HIV in 2016, 
which is estimated to be the third largest population of HIV affected 
people in the world. In 2016, HIV prevalence in India was estimated at 
0.3%, and 62,000 people died from AIDS-related illnesses. Estimated 
numbers of new HIV infections in 2016 were 80 thousand and 1 million 
people are on ART who are living with HIV. The number of people newly 
initiating ART in 2016 was 176969 [7].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Growing socioeconomic burden of the disease in India led to the 
inception of National AIDS Control Organization (NACO) in 1986 and 
subsequently in the formation of National AIDS Programme in 1987. 
ART became the keystone of National AIDS Programme [8].
ART involves a combination of at least three or more HIV medicines 
from at least two classes of antiretroviral agents called highly active 
ART refer to as Anti-HIV “cocktail,” given to the patients every day. It can 
slow the disease progression by preventing the virus from multiplying 
and destroying the CD4 cells, thus decreases the amount of virus in an 
infected persons’ blood (viral load) and restore the immune system [9].
There are mainly six major classes of antiretroviral agents:
1. Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs/
NtRTIs) - zidovudine, abacavir, didanosine, emtricitabine, lamivudine, 
stavudine, and tenofovir.
2. Non-nucleoside reverse transcriptase inhibitors - efavirenz and 
nevirapine.
3. Protease inhibitors - atazanavir, lopinavir, and ritonavir.
4. Integrase inhibitors - raltegravir.
5. Fusion inhibitors - enfuvirtide.
6. Chemokine receptor antagonists (CCR5 antagonists) - Maraviroc.
There is also a medicine called cobicistat which increases the action 
of antiretrovirals but does not have any effect on the virus itself. 
Each drug class disrupts different stages of viral life cycle [10]. The 
documented side effects of these drugs are: Zidovudine causes bone 
marrow suppression leading to anemia and neutropenia. Stavudine 
causes nausea, peripheral neuropathy, pancreatitis, and lipoatrophy. 
Nevirapine causes skin rash, Steven Johnson Syndrome (SJS) and 
hepatitis. Efavirenz causes skin rash in 10% of patients. Lamivudine has 
minimum toxicity. Most common adverse effects of lamivudine were 
diarrhea, malaise, fatigue, headache, and sleep disturbances [11]. In our 
study, we observed the various ADRs to ART in HIV/AIDS patients and 
assessed causality, severity, and preventability of the reported ADRs at 
ART center Netaji Subhash Chandra Bose Medical College, Jabalpur M.P.
METHODS
After approval from the Institutional Ethics Committee, the study was 
jointly conducted in the Department of Pharmacology and ART center 
of N.S.C.B. Medical College, Jabalpur (MP), from March 2016 to July 
2017. It was a prospective as well as a retrospective observational 
study with a sample size of 260. The participants had been offered to 
voluntarily participate in the study. They had given written informed 
consent before they were enrolled in the study.
Inclusion Criteria
The following criteria were included in this study:
1. Patients of any age of either sex.
2. Both new and old registered patients who were on ART.
3. Patients who gave written informed consent.
Exclusion Criteria
The following criteria were excluded from this study:
1. Patients who do not give informed consent for participation in the 
study.
2. Patients who were not able to recall or explain the symptoms of ADR.
3. Patients unable to respond to verbal questions.
Every enrolled patient who was already on ART and who has newly 
started the ART during this study period, were observed. These 
patients were provided with Informed Consent Form, and their consent 
for the study was documented. Details of the participants were kept 
confidential. Detailed history of the patient including demographic 
detail, past and present illness, and concurrent systemic illness, and 
drug history was taken along with detailed clinical examination when 
the patient came for follow-up visits to ART center. These informations 
were recorded on a pre-designed patient pro forma and correlated with 
prefilled patient treatment records (white card). Essential laboratory 
investigations such as complete blood counts, liver function tests, renal 
function tests, lipid profile, blood sugar tests, and CD4 count were done 
or recorded from prefilled patient treatment records.
All the ADRs were duly filled up in the suspected adverse drug reaction 
reporting form of Central Drugs Standard Control Organization by 
interviewing with patient or patients’ caretaker and by reviewing 
prefilled patient treatment records. To establish the etiologic agents 
for ADR, attention was paid to the drug history, speculating the 
temporal correlation with the drug, duration of ADR, type of reaction, 
improvement in reaction on withdrawal of drug and recurrence of 
reaction on rechallenge if possible. These ADR was further assessed for 
its causality, preventability, and severity using WHO-UMC criteria [12], 
Modified Schumock and Thornton criteria [13], and Modified Hartwig 
and Siegel scale [14], respectively. The data were analyzed using SPSS 
20. Appropriate univariate and bivariate statistical analysis was carried 
out using the student’s t-test for the continuous variable (age) and two-
tailed Fisher exact test or Chi-square (χ2) test for categorical variables. 
All means are expressed as mean ± standard deviation and proportion 
in percentages. The critical levels of significance of the results were 
considered at 0.05 levels, i.e., p<0.05 was considered significant.
RESULTS
A total of 260 patients were enrolled in our study in which 47.7% were 
males and 52.3% females. Only 220 (84.6%) patients developed ADRs 
among them 47.3% were males and 52.7% were females. A total of 
425 ADRs were observed of which 41% occurred in males and 59% 
in females (Table 1). Majority 68.2% of the cases was observed in 
21–40 years in ADR+ group followed by 22.3% in 41–60 years in the 
same. The mean age of cases in ADR+ group was observed to be 34.06 
(±11.12) years. Statistically, cases with ADR belonged to significantly 
higher (p<0.001) mean age (Table 2). 45% and 38.6% of patients who 
experience ADRs were on regimen TLE and ZLN, respectively. Maximum 
51.7% of ADRs were caused by TLE followed by 37% with ZLN regimen 
(Table 3).
Table 1: Gender distribution
Gender Total 
n=260 (%)
ADR+n = 220 (%) Total ADRs 
n=425 (%)
Male 124 (47.7) 104 (47.3) 174 (41)
Female 136 (52.3) 116 (52.7) 251 (59)
χ2=0.10; P>0.05 at 1df, ADRs: Adverse drug reactions
Table 2: Age distribution
Age (years) Total 
n=260 (%)
ADR+n = 220 (%) Total ADRs 
n=425 (%)
0–20 24 (9.2) 17 (7.7) 28 (6.6)
21–40 179 (69) 150 (68.2) 298 (70.1)
41–60 53 (20.3) 49 (22.3) 86 (20.2)
>60 4 (1.5) 4 (1.8) 13 (3.1)
Mean±SD 33.09±11.236 34.06±11.123
t=3.33; P<0.001, ADRs: Adverse drug reactions
Table 3: Drug regimens and patients found with ADRs
Regimen Total patients 
n=260 (%)




ALN 8 (3.1) 7 (3.2) 8 (1.9)
SLN 21 (8.1) 17 (7.7) 22 (5.2)
TLE 121 (46.5) 99 (45) 220 (51.7)
TLN 8 (3.1) 7 (3.2) 10 (2.3)
ZLE 5 (1.9) 5 (2.3) 8 (1.9)
ZLN 97 (37.3) 85 (38.6) 157 (37)
χ2=2.63; P>0.05 at 5df, ADRs: Adverse drug reactions
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Most common ADRs were dizziness 18.6%, rashes 14.6%, anemia 
10.6%, and vomiting 6.6%. Dizziness and rashes are mainly caused by 
TLE and ZLN, respectively. Nightmares 2.6% and renal toxicity 3.3% 
are found only in TLE. Lipodystrophy 1.4% occurred by SLN and TLE. 
Anemia 10.6% and neutropenia 3.3% mainly occurred in ZLN. Excessive 
sweating 0.9% and hair fall 1.4% occurred in TLE and ZLN, respectively. 
Only 2 patients had SJS, in ZLN (Table 4).
Table 5 shows interventions taken after experiencing ADR by different 
regimens. 2.3% patients of SLN and 8.6% patients of ZLN were switched 
to SLE and ZLE regimen, respectively. 7.3% patients were switch to SLN 
who were on ZLN regimen. 15% of patients were allowed to withhold 
the treatment. Thus, the change in the regimen was applied as an 
interventional tool in 40% of the patients to alleviate there ADRs.
Causality assessment as per the WHO-UMC causality scale shows that 
98 (44.5%) patients, among a total of 220, had possible affiliation to the 
offending drug while 122 (55.5%) patients had a probable association 
to the drugs (Table 6). Preventability assessment according to modified 
Schumock and Thornton scale shows that of 220 patients who were 
found to have ADRs in our study, 186 (84.5%) patients would not be 
prevented while 34 (15.5%) patients would probably be prevented 
(Table 7). Table 8 shows that majority of patients were categorized in 
to mild and moderate in terms of severity assessment of ADR’s using 
modified Hartwig and Siegel scale.
DISCUSSION
A total of 260 patients were observed during the study period of 
18 months. Patients developed ADRs with the incidence rate of 84.6%. 
Sharma et al. [15] found the incidence rate of 71.1% which was less 
than ours whereas Nagpal et al. [16] reported that 90.64% patients 
experienced ADRs which were higher as compared to our study. Our 
study showed a higher prevalence of ADR in female (52.7%) than male 
(47.3%). Similar finding was also reported by Sadiq et al. [17], with 
a higher prevalence in female (64%) as compared to male (36%). In 
contrast, Khan et al. [18] reported a higher prevalence of ADRs in male 
(74.8%) than female (25.2%). The factors of the gender differences 
Table 4: Various ADRs among different regimens
System ADR ALN (n=8) SLN (n=22) TLE (n=220) TLN (n=10) ZLE (n=8) ZLN (n=157) Total 
ADR (n=425) [%]
CNS Depression 6 6 (1.4)
Dizziness 1 70 1 7 79 (18.6)
Drowsiness 8 8 (1.9)
Headache 7 5 12 (2.8)
Insomnia 9 9 (2.1)
Neuropathy 5 3 1 9 (2.1)
Nightmares 11 11 (2.6)
Psychosis 5 1 6 (1.4)
Suicidal tendency 2 2 (0.5)
GIT Anorexia 9 1 9 19 (4.5)
Diarrhea 1 2 3 (0.7)
Gastritis 4 2 6 (1.4)
Nausea 1 11 8 20 (4.7)
Pancreatitis 1 1 2 (0.5)
Vomiting 1 18 9 28 (6.6)
Hepatorenal Jaundice 1 5 6 (1.4)
Renal toxicity 14 14 (3.3)
Dermatological Excessive sweating 4 4 (0.9)
Hair fall 6 6 (1.4)
Hyper Pigmentation 2 3 5 (1.2)
Itching 4 2 6 12 (2.8)
Rashes 7 9 8 6 32 62 (14.6)
Steven-Johnson Syndrome 2 2 (0.5)
Hematological Anemia 1 4 40 45 (10.6)
Neutropenia 2 12 14 (3.3)
Others Fatigue 12 1 4 17 (4.0)
Fever 1 3 4 (0.9)
Giddiness 1 2 3 (0.7)
Lipodystrophy 3 3 6 (1.4)
Myalgia 4 1 5 (1.2)
ADRs: Adverse drug reactions, CNS: Central nervous system
Fig. 2: Age distribution
Fig. 1: Gender distribution
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for the appearance of ADRs might be due to hormonal effects, drug 
metabolism, fat composition, body mass index, immunological status, 
environmental factor, or genetic constitutional differences at the level 
of various enzymes.
Majority of the patients (69%) belong to the age group of 21–40 years 
followed by the group between ages 41 and 60 years (20.3%). This is 
comparable to the study of Sehgal et al. [19] who found that a large 
number of patients (74.9%) belongs to the same age group.
Of total 425 ADRs, 51.7% occurred in patients who were on TLE 
regimen, 37% in the patients on ZLN regimen and remaining by others 
regimens. This is in accordance with Kumar et al. [20] where maximum 
ADRs amounting to 49.23% and 23.85% were observed with patients 
on TLE and ZLN regimen, respectively.
Most common ADR observed was dizziness 18.6%, rashes 14.6%, anemia 
10.6%, vomiting 6.6%, and nausea 4.7% in our study. Jain et al. [21] also 
found dizziness 22.6% to be the most common ADR. Similar findings 
were also observed by Sehgal et al. [19]where dizziness was the most 
common central nervous system (CNS) adverse effect while Singh 
et al. [22] found peripheral neuropathy (20.8%) as the most common 
ADR in their study. Other CNS ADRs were headache 2.8%, nightmares 
2.6%, insomnia 2.1%, neuropathy 2.1%, drowsiness 1.9%, psychosis 
1.4%, depression 1.4%, and suicidal tendencies 0.5% as observed in 
our study which is caused by TLE regimen except for neuropathy which 
occurred mainly due to SLN regimen. This is in concordance with the 
study of Nagpal et al. [16]and Reddy et al. [23]. We found that efavirenz 
is commonly associated with CNS ADRs as observed by Sehgal et al. [19]
and Kumar et al. [20]. This is mainly because of the hydroxylation of 
efavirenz to 8-hydroxy efavirenz, through CYP2B6, which is the main 
metabolite causing CNS toxicity. Acute psychosis and suicidal tendency 
were reported as new ADRs in our study. One case of these was found 
to be as severely life-threatening, and remaining 5 were moderate 
in nature. It is very difficult to distinguish whether they are due to 
newly diagnosed disease origin or induced due to drug therapy. In 
such cases, we need psychiatric intervention. Mild to moderate cases 
of neuropathy were reported as tingling, numbness or paresthesia 
and in severe form permanent nerve damage due to stavudine-based 
regimens. We observed mild to moderate cases of neuropathy. As an 
intervention in peripheral neuropathy, we changed the regime and gave 
symptomatic treatment in the form of multivitamins. Newly started 
TLE causes dizziness as the most common side effect which subsided 
after 3–4 weeks with the regime being continued. The patient can be 
managed alone by counseling or assurance.
Vomiting 6.6%, nausea 4.7%, and anorexia 4.5% were the most common 
gastrointestinal ADRs followed by gastritis 1.4%, diarrhea 0.7%, and 
pancreatitis 0.5% in our study. 42.4% ADRs were gastrointestinal 
among all reported ADRs by Nagpal et al. [16] which comprised 
anorexia 24.8%, gastritis 14.1%, diarrhea 11.8%, nausea 7.2%, and 
vomiting 6.5%. Khan et al. [18] observed pancreatitis 3.1%, diarrhea 
1.4%, and vomiting 0.7% in their study. Sharma et al. [15] observed 
gastritis 10%, anorexia 1.1%, diarrhea 1.1%, and pancreatitis 1.1% in 
their study. Reddy et al. [23] also reported the most common ADR in 
their study to be gastrointestinal with gastritis 13.13%, anorexia 6.8%, 
and nausea 2.5%. In our study, most of GIT side effects are caused by 
TLE and ZLN regimen. This is in concordance with Kumari et al. [24] 
who found that maximum gastrointestinal ADRs occurred with TLE and 
ZLN regimen.
Nearly 1.4% of ADRs reported were jaundice and renal toxicity to be 
having an incidence of 3.3%. Weldegebreal et al. [25]reported jaundice 
to be at 1.6% which was comparable to our study. Rather et al. [26] 
found renal toxicity (elevated serum creatinine) to be 3% which was 
also comparable to our study. Jaundice as nonspecific ADR can cause 
by all type of regimens but in our study mostly caused by ZLN and SLN 
(attributed to nevirapine) which appear in the form of the increased 
liver enzyme. In severe cases, elevated liver enzyme can rise to 5 times. 
Table 5: Interventions after ADRs
Interventions after ADRs Previous regimens Total n=220 (%)
ALN (n=7) SLN (n=17) TLE (n=99) TLN (n=7) ZLE (n=5) ZLN (n=85)
Switch to SLE 5 5 (2.3)
Switch to SLN 16 16 (7.3)
Switch to TLE 1 9 6 3 29 48 (21.8)
Switch to ZLE 19 19 (8.6)
Counseling (Couns.) 45 1 46 (21)
Counseling with Symp. t/t 1 40 12 53 (24)
Withhold 6 2 14 2 9 33 (15)
ADRs: Adverse drug reactions
Table 6: Causality assessment
Causality assessment Number of patients n=220 (%)
Possible 98 (44.5)
Probable 122 (55.5)
Table 7: Preventability assessment
Preventability assessment Number of patients n=220 (%)
Not preventable 186 (84.5)
Probably preventable 34 (15.5)
Table 8: Severity assessment




Fig. 3: Drug regimens and patients found with adverse drug 
reactions
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Such cases want withholding the treatment until full recovery and 
restart an alternative therapy with close monitoring. Weldegebreal 
et al. [25] were in support of our observation where jaundice was 
caused by zidovudine-based regimen. Rather et al. [26] correlated 
hepatitis due to NRTIs which were also similar to our results. Renal 
toxicity was found mainly in TLE/tenofovir-based regimen which 
is concordance to Kumar et al. [20]. It is in the form of raised serum 
creatinine, increased uric acid or reduced creatinine clearance. When it 
occurs, therapy has to be withdrawn up to full recovery and adjustment 
of doses as per creatinine clearance.
It is a challenging task for the treating physician to distinguish whether 
the symptoms are due to the illness itself or through the drugs, however 
on withdrawing the drug if symptoms subside or resolve then it is in the 
favor of drug-induced reaction while if the symptoms worsen then it 
may be due to the illness itself.
Among dermatological reactions, rash 14.6%, itching 2.8%, hair fall 
1.4%, hyperpigmentation 1.2%, excessive sweating 0.9%, and SJS 0.5%, 
were observed in our study. Masenyetse et al. [27] found the incidence 
of rash to be at 15% which is similar to our finding. Hyperpigmentation 
14.4%, itching 7.7%, SJS 3.3%, and hair loss 2.2% were found in the 
study by Sharma et al. [15] which is in support of our study. In our study, 
dermatological ADRs were mostly associated with ZLN regimen which 
is in concordance with Sharma et al. [15] and Reddy et al. [23] who also 
found that most of the cutaneous ADRs were due to ZLN regimen.
In our study, five cases of rashes were mild in nature and some of which 
are associated with itching. They occurred with the initiation of therapy 
and subsided after 1–2 weeks with symptomatic treatment. 20 cases 
were moderate to severe in nature which was managed by a change 
in the regimen and or withholding the treatment. Most of the rashes 
were maculopapular in type which is caused mainly by nevirapine, 
Fig. 4: Various adverse drug reactions among different regimens
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Rather et al. [26] were too in concordance with our study who also 
found rashes to be caused by nevirapine while Weldegebreal et al. [25]
observed skin rashes with zidovudine- and tenofovir-based regimen. 
Two cases of Steven-Johnson Syndrome were reported which required 
intensive care. It was very severe in form with generalized bulbous 
eruptions, mainly due to ZLN regimen and required withholding the 
therapy until full recovery and further switching to another therapy. 
Sharma et al. [15] and Reddy et al. [23] also showed the occurrence of 
rash to be caused by nevirapine-containing regimen.
Hematological ADRs, mostly due to zidovudine-based regimen, 
were anemia 10.6% and neutropenia 3.3%. Zidovudine causes bone 
marrow suppression which is the main factor for its causing anemia 
and neutropenia. Rather et al. [26] were too in supports to our study, 
where they observed anemia 58.6% and neutropenia 11.1% as the 
hematologic ADRs occurring with the zidovudine-based regimen. Three 
cases of severe anemia were reported with the hemoglobin of <5 g% 
and remaining cases under moderate anemia with the hemoglobin 
range of 6–8 g%. Only three cases required withhold of treatment, and 
remaining were changed to another therapy with hematinics or blood 
transfusion. Abdissa et al. [28]are also in accordance to our study who 
found severe toxicities as anemia 32% and neutropenia 29.5% in their 
study.
Others ADRs such as fatigue 4%, lipodystrophy 1.4%, myalgia 1.2%, fever 
0.9%, and giddiness 0.7% were also reported in our study. Sadiq et al. [17]
and Reddy et al. [23] found similar types of ADRs in their studies.
Patients who experienced ADRs were managed by switching one drug 
or whole regimen (40%). Patients who developed severe ADRs were 
Fig. 5: Interventions after adverse drug reactionsAQ1
Fig. 8: Severity assessment
Fig. 6: Causality assessment
Fig. 7: Preventability assessment
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allowed to withhold (15%) the treatment until full recovery. Majority 
of mild to moderate cases of ADR were managed by counseling (21%) 
and or symptomatic treatment (24%). Our finding was similar to Luma 
et al. [29] where 68.2% patients needed the change in the regimen, and 
31.8% were maintained on the same regimen with their ADRs subsided 
through symptomatic treatment. Abdissa et al. [28] showed that 10% of 
the patients required withhold of their therapy or change in treatment 
due to severe toxicity.
As per Modified Schumock and Thornton scale, most of the ADR 
were not preventable (84.5%), while 15.5% of ADRs were probably 
preventable. Similar observation was seen by Kumari et al. [24] where 
the majority of ADRs (83.33%) were not preventable, but Modayil 
et al. [31] found that 88% of ADRs were probably preventable which 
was contrary to our findings.
According to Modified Hartwig and Siegel severity assessment scale of 
ADRs, 84 (38%) were mild, 123 (56%) were moderate, and 13 (6%) 
were severe in nature. Similar type of results was found by Anwikar 
et al. [30]where 8.77%, 77%, and 14.02% ADRs were mild, moderate, 
and severe, respectively. These results are in contrast to Sadiq et al. [17] 
and Kumar et al. [20] where the majority of ADRs were mild followed by 





Antiretroviral although, the milestone for the treatment of HIV/AIDS 
has very high potential for developing ADRs which mainly affects the 
CNS, GIT, hematological, dermatological, and hepatorenal system. The 
TLE regimen prescribed as per the WHO and NACO guidelines cause 
mainly CNS ADRs, especially with efavirenz. These ADRs were mild 
to moderate in nature and subside spontaneously after 2–3 weeks 
without discontinuing the treatment. Maximum ADRs were managed 
by counseling and or symptomatically. Some drugs such as zidovudine 
and stavudine show ADRs such as anemia, neutropenia, and peripheral 
neuropathy after long-term treatment. Hence, active PV is needed for 
identification, prevention, and management of such ADRs developed by 
ART. This ensures not only the safety of the patients but also compliance 
to the treatment which is necessary for optimal therapeutic outcomes 
and to improve quality of life.
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